AU6909098A
(en)
*
|
1996-10-31 |
1998-05-22 |
Human Genome Sciences, Inc. |
Streptococcus pneumoniae polynucleotides and sequences
|
US6676943B1
(en)
|
1997-04-24 |
2004-01-13 |
Regents Of The University Of Minnesota |
Human complement C3-degrading protein from Streptococcus pneumoniae
|
US7129339B1
(en)
|
1997-07-02 |
2006-10-31 |
Sanofi Pasteur Limited |
Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
|
US6800744B1
(en)
*
|
1997-07-02 |
2004-10-05 |
Genome Therapeutics Corporation |
Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
|
TR200002437T2
(tr)
|
1998-02-20 |
2000-11-21 |
Biochem Pharma Inc. |
B grubu streptococcus antijenleri.
|
DE69942176D1
(de)
*
|
1998-04-07 |
2010-05-06 |
Medimmune Llc |
Choline-bindende proteine derivate aus pneumokoken als impfstoff
|
PL204863B1
(pl)
|
1998-07-22 |
2010-02-26 |
Stichting Dienst Landbouwkundi |
Zastosowanie mutanta Streptococcus, szczepionka i sposoby kontrolowania lub eliminowania choroby paciorkowcowej w populacji
|
US20030134407A1
(en)
|
1998-07-27 |
2003-07-17 |
Le Page Richard William Falla |
Nucleic acids and proteins from Streptococcus pneumoniae
|
EP1801218A3
(en)
*
|
1998-07-27 |
2007-10-10 |
Sanofi Pasteur Limited |
Nucleic acids and proteins from streptococcus pneumoniae
|
EP1950302B1
(en)
|
1998-12-23 |
2012-12-05 |
ID Biomedical Corporation of Quebec |
Streptococcus antigens
|
US7128918B1
(en)
*
|
1998-12-23 |
2006-10-31 |
Id Biomedical Corporation |
Streptococcus antigens
|
EP1141306B1
(en)
*
|
1998-12-23 |
2008-05-07 |
ID Biomedical Corporation |
Streptococcus antigens
|
CA2366152A1
(en)
*
|
1999-03-19 |
2000-09-28 |
Smithkline Beecham Biologicals S.A. |
Streptococcus pneumoniae vaccine
|
US6887480B1
(en)
*
|
1999-06-10 |
2005-05-03 |
Medimmune, Inc. |
Streptococcus pneumoniae proteins and vaccines
|
WO2001096368A2
(en)
*
|
2000-06-14 |
2001-12-20 |
Cytovax Biotechnologies, Inc. |
Use of coiled-coil structural scaffold to generate structure-specific peptides
|
US7074415B2
(en)
*
|
2000-06-20 |
2006-07-11 |
Id Biomedical Corporation |
Streptococcus antigens
|
AU2001270381B2
(en)
*
|
2000-06-20 |
2007-05-24 |
Id Biomedical Corporation |
Streptococcus antigens
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
EP1368373B1
(en)
|
2001-02-02 |
2011-04-27 |
Stichting Dienst Landbouwkundig Onderzoek |
Environmentally regulated genes, involved in the virulence of streptococcus suis
|
US7262024B2
(en)
|
2001-12-20 |
2007-08-28 |
Id Biomedical Corporation |
Streptococcus antigens
|
US8229903B2
(en)
*
|
2002-12-19 |
2012-07-24 |
International Business Machines Corporation |
Suggesting data interpretations and patterns for updating policy documents
|
JP5280199B2
(ja)
|
2005-06-27 |
2013-09-04 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
EP1754717A1
(en)
|
2005-08-19 |
2007-02-21 |
Université de Lausanne |
Antigenic peptides and their use
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
EP3470080A1
(en)
*
|
2005-12-22 |
2019-04-17 |
GlaxoSmithKline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
NZ575272A
(en)
|
2006-09-07 |
2012-02-24 |
Glaxosmithkline Biolog Sa |
Inactivated poliovirus type 1, diptheria toxoid, tetanus toxoid and killed whole-cell Bordetella pertussis vaccine
|
CA2683748C
(en)
|
2007-04-13 |
2016-02-16 |
The Board Of Regents Of The University Of Oklahoma |
Mutants of cholesterol-dependent cytolysins and uses thereof
|
US20100074918A1
(en)
|
2007-05-02 |
2010-03-25 |
Jan Poolman |
Vaccine
|
KR20100045445A
(ko)
|
2007-06-26 |
2010-05-03 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
|
BRPI0814127A2
(pt)
|
2007-07-23 |
2015-02-03 |
Sanofi Pasteur Ltd |
Polipeptídeos imunegênicos e anticorpos monoclonais
|
US20160228500A9
(en)
*
|
2007-07-23 |
2016-08-11 |
Martina Ochs |
Immunogenic Polypeptides and Monoclonal Antibodies
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
EP2023143A1
(en)
*
|
2007-08-06 |
2009-02-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Immunogenic streptococcus proteins
|
AU2009222105B2
(en)
|
2008-03-03 |
2012-05-17 |
Novartis Ag |
Compounds and compositions as TLR activity modulators
|
SI2271360T1
(sl)
|
2008-04-16 |
2015-12-31 |
Glaxosmithkline Biologicals S.A. |
Cepivo
|
CA2738245A1
(en)
|
2008-09-26 |
2010-04-01 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
EP3017826A1
(en)
|
2009-03-24 |
2016-05-11 |
Novartis AG |
Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
|
WO2010125480A1
(en)
|
2009-04-30 |
2010-11-04 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
WO2010132833A1
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
US9517263B2
(en)
|
2009-06-10 |
2016-12-13 |
Glaxosmithkline Biologicals Sa |
Benzonaphthyridine-containing vaccines
|
AU2010290896B2
(en)
|
2009-09-02 |
2014-07-03 |
Glaxosmithkline Biologicals S.A. |
Immunogenic compositions including TLR activity modulators
|
TWI445708B
(zh)
|
2009-09-02 |
2014-07-21 |
Irm Llc |
作為tlr活性調節劑之化合物及組合物
|
MX2012002639A
(es)
|
2009-09-03 |
2012-03-14 |
Pfizer Vaccines Llc |
Vacuna de pcsk9.
|
JP2013504556A
(ja)
|
2009-09-10 |
2013-02-07 |
ノバルティス アーゲー |
気道疾患に対する組み合わせワクチン
|
WO2011057148A1
(en)
|
2009-11-05 |
2011-05-12 |
Irm Llc |
Compounds and compositions as tlr-7 activity modulators
|
CA2784580A1
(en)
|
2009-12-15 |
2011-07-14 |
Novartis Ag |
Homogeneous suspension of immunopotentiating compounds and uses thereof
|
WO2011075822A1
(en)
|
2009-12-22 |
2011-06-30 |
Sanofi Pasteur Limited |
Immunogenic compositions and related methods
|
KR20120107121A
(ko)
*
|
2009-12-22 |
2012-09-28 |
사노피 파스퇴르 리미티드 |
면역원성 조성물
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
EA031379B1
(ru)
|
2010-03-23 |
2018-12-28 |
Новартис Аг |
Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
EP2646049B1
(en)
|
2010-12-03 |
2018-05-02 |
Sanofi Pasteur Limited |
Composition for immunization against streptococcus pneumoniae
|
EP2680883B1
(en)
|
2011-03-02 |
2018-09-05 |
Pfizer Inc |
Pcsk9 vaccine
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
MX339058B
(es)
|
2011-05-17 |
2016-05-09 |
Glaxosmithkline Biolog Sa |
Vacuna contra streptococcus pneumoniae.
|
EP2822586A1
(en)
|
2012-03-07 |
2015-01-14 |
Novartis AG |
Adjuvanted formulations of streptococcus pneumoniae antigens
|
CN105188747A
(zh)
|
2013-02-01 |
2015-12-23 |
葛兰素史密斯克莱生物公司 |
包含toll样受体激动剂的免疫组合物的皮内递送
|
US11576958B2
(en)
|
2013-02-07 |
2023-02-14 |
Children's Medical Center Corporation |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP3096783B1
(en)
|
2014-01-21 |
2021-07-07 |
Pfizer Inc. |
Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
|
EP3096786B1
(en)
|
2014-01-21 |
2021-07-07 |
Pfizer Inc. |
Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
|
PE20161095A1
(es)
|
2014-01-21 |
2016-10-26 |
Pfizer |
Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos
|
CA2939416A1
(en)
|
2014-02-14 |
2015-08-20 |
Pfizer Inc. |
Immunogenic glycoprotein conjugates
|
AU2015349787B2
(en)
|
2014-11-21 |
2021-07-29 |
The Board Of Regents Of The University Of Oklahoma |
Pneumolysin mutants and methods of use thereof
|
MX2017009308A
(es)
|
2015-01-15 |
2017-11-08 |
Pfizer |
Composiciones inmunogenicas para usar en vacunas neumococicas.
|
KR20230058726A
(ko)
|
2015-07-21 |
2023-05-03 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
JP6884145B2
(ja)
|
2015-11-20 |
2021-06-09 |
ファイザー・インク |
肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
PL3570879T3
(pl)
|
2017-01-20 |
2022-06-20 |
Pfizer Inc. |
Kompozycje immunogenne do zastosowania w szczepionkach przeciw pneumokokom
|
EP3752182B1
(en)
|
2018-02-12 |
2024-05-15 |
Inimmune Corporation |
Toll-like receptor ligands
|
CN112673054A
(zh)
|
2018-07-19 |
2021-04-16 |
葛兰素史密丝克莱恩生物有限公司 |
用于制备干燥多糖的方法
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US20220016229A1
(en)
|
2018-12-12 |
2022-01-20 |
Pfizer Inc. |
Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
EP3952906A1
(en)
|
2019-04-10 |
2022-02-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
CN114728050A
(zh)
|
2019-07-31 |
2022-07-08 |
圣诺菲·帕斯图尔公司 |
多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法
|
MX2022005252A
(es)
|
2019-11-01 |
2022-06-08 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
EP4107192A1
(en)
|
2020-02-21 |
2022-12-28 |
Pfizer Inc. |
Purification of saccharides
|
KR20220143910A
(ko)
|
2020-02-23 |
2022-10-25 |
화이자 인코포레이티드 |
에스케리키아 콜라이 조성물 및 그의 방법
|
CA3199094A1
(en)
|
2020-10-22 |
2022-04-28 |
Pfizer Inc. |
Methods for purifying bacterial polysaccharides
|
MX2023004912A
(es)
|
2020-10-27 |
2023-05-16 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
CN116744965A
(zh)
|
2020-11-04 |
2023-09-12 |
辉瑞大药厂 |
用于肺炎球菌疫苗的免疫原性组合物
|
IL302449A
(en)
|
2020-11-04 |
2023-06-01 |
Eligo Bioscience |
CUTIBACTERIUM ACNES PHAGES RECOMBINANT, the production method and their uses
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
JP2024517780A
(ja)
|
2021-05-03 |
2024-04-23 |
ファイザー・インク |
細菌およびベータコロナウイルス感染症に対するワクチン接種
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
EP4346893A2
(en)
|
2021-05-28 |
2024-04-10 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
KR20230175284A
(ko)
|
2021-05-28 |
2023-12-29 |
화이자 인코포레이티드 |
접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
|
KR20240128715A
(ko)
|
2022-01-13 |
2024-08-26 |
화이자 인코포레이티드 |
접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024201324A2
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024214016A1
(en)
|
2023-04-14 |
2024-10-17 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024224266A1
(en)
|
2023-04-24 |
2024-10-31 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|